Cellular IL-10 is more effective than viral IL-10 in decreasing venous thrombosis

被引:15
|
作者
Myers, DD
Hawley, AE
Farris, DM
Chapman, AM
Wrobleski, SK
Henke, PK
Wakefield, TW
机构
[1] Univ Michigan, Jobst Vasc Res Labs, Unit Lab Anim Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Surg, Vasc Surg Sect, Ann Arbor, MI 48109 USA
关键词
interleukin-10; viral interleukin-10; venous thrombosis; in vivo rodent animal model;
D O I
10.1016/S0022-4804(03)00144-6
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Systemic administration of cellular interleukin-10 (cIL-10) and gene transfection of viral interleukin-10 (vIL-10) at thrombus induction decreases vein wall inflammation. Only cIL-10, despite sharing an 84% amino acid sequence homology with vIL-10, decreases thrombosis through mechanisms yet to be determined. Methods. C57BL/6 mice (Mus musculus, n99) were studied. Inferior vena caval thrombosis was created by inferior vena caval ligation and the animals were sacrificed and evaluated at days 2 and 6 after ligation. At thrombus induction groups received intravenous 0.25 mug of cIL-10, 0.25 mug of vIL-10, or saline (untreated controls). Evaluations included thrombus mass and vein wall leukocyte counts, protein levels, and reverse-transcription polymerase chain reaction mRNA levels of P- and E-selectin, monocyte chemotactic protein-1, and IL-10. Groups were compared by analysis of variance and t tests. Results. Less thrombus was noted at both days 2 and 6 in animals treated with cIL-10. At day 2 only, vein wall leukocyte counts revealed a significant decrease in neutrophils in cIL-10 animals versus controls, with no significant differences for vIL-10 animals. In cIL-10-treated animals, P-selectin protein levels were decreased at day 6, along with a decreased thrombus mass, without significant differences in E-selectin monocyte chemotactic protein-1, or IL-10 protein levels. vIL-10 treated animals showed increased E-selectin mRNA and thrombus mass versus controls on day 6. Conclusions. cIL-10 is more antithrombotic/anti-inflammatory than vIL-10. This may be the result of cIL-10 decreasing P-selectin protein expression and vIL-10 increasing E-selectin mRNA levels. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 50 条
  • [41] IL-10: Evolving concepts
    Borish, L
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (03) : 293 - 297
  • [42] IL-10 and the resolution of infections
    Filippi, C. M.
    von Herrath, M. G.
    JOURNAL OF PATHOLOGY, 2008, 214 (02): : 224 - 230
  • [43] IL-10 in myeloma cells
    Otsuki, T
    Yata, K
    Sakaguchi, H
    Uno, M
    Fujii, T
    Wada, H
    Sugihara, T
    Ueki, A
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 969 - 974
  • [44] A synthetic IL-10 mimic
    Natalie DeWitt
    Nature Biotechnology, 1999, 17 (3) : 214 - 214
  • [45] IL-10 INHIBITS EAE
    SKIAS, DD
    REDER, AT
    NEUROLOGY, 1995, 45 (04) : A349 - A349
  • [46] Opposing effects of IL-10
    Elisabeth Kugelberg
    Nature Reviews Immunology, 2014, 14 : 357 - 357
  • [47] The dual role of IL-10
    Mocellin, S
    Panelli, MC
    Wang, E
    Nagorsen, D
    Marincola, FM
    TRENDS IN IMMUNOLOGY, 2003, 24 (01) : 36 - 43
  • [48] IL-10 and pregnancy complications
    Azizieh, F. Y.
    Raghupathy, R.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2017, 44 (02): : 252 - 258
  • [49] IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
    Ouyang, Wenjun
    O'Garra, Anne
    IMMUNITY, 2019, 50 (04) : 871 - 891
  • [50] Antisense IL-10 abrogates the inhibitory effects of IL-10 production by transfected tumor cells
    Parker, G
    Fernandes, H
    Chong, SY
    Czarneski, J
    Ra, H
    Lin, YC
    Raveche, E
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 2000, 6 (03) : 113 - 119